Skip to main content
Clinical Trials/NCT00890734
NCT00890734
Completed
Phase 2

A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial

Cytos Biotechnology AG1 site in 1 country63 target enrollmentStarted: April 2009Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
63
Locations
1
Primary Endpoint
Markers for inflammation and asthma

Overview

Brief Summary

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids
  • Further criteria as defined in the study protocol

Exclusion Criteria

  • Use of oral corticosteroids within past 3 months
  • Hospitalization for asthma exacerbation within past 6 months
  • Uncontrolled asthma
  • Contraindication to any study test or procedure
  • Further criteria as defined in the study protocol

Arms & Interventions

1

Experimental

Intervention: CYT003-QbG10 (Drug)

2

Placebo Comparator

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Markers for inflammation and asthma

Time Frame: 1-3 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials